TrialVaccine2022

Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.

Jessica W Crothers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.